Logo

Celgene Amends its Existing Collaboration with Editas to Develop and Commercialize Autologous and Allogeneic T Cell Medicines for Cancer and Autoimmune Diseases

Share this

Celgene Amends its Existing Collaboration with Editas to Develop and Commercialize Autologous and Allogeneic T Cell Medicines for Cancer and Autoimmune Diseases

Shots:

  • Editas to receive $70M up front- milestone and royalty payments for each therapy developed by Celgene and will develop genome editing tool for which Celgene has right to opt-in to such genome editing tools for the development of gene-edited alpha-beta T cell therapies
  • In May’2015- Editas and Juno entered into an exclusive collaboration to develop CAR T and TCR Cell Therapies- under which Editas has received $25M as upfront & ~$22M to support research over the next five years across the three programs in the alliance along with $230M research- regulatory- and commercial milestones and royalties for each program
  • The amended agreement replaces the original agreement- allowing Editas to develop non-alpha-beta T cell therapies while expanding Celgene’s access to gene-edited alpha-beta T cells beyond oncology

Click here to­ read full press release/ article | Ref: Editas  | Image: The Boston Globe


Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions